BREAKING:ETHEREUM JUST BROKE $2,800 🚀 https://t.co/bPP0YYe7Wd ...

Short-term volatility in Europe’s natural gas market dropped to the lowest level in nearly four years as ample supply overshadows concerns about potential demand spikes across the globe https://t.co/gbK86tZwdo ...

Investment Activity - BlackRock has purchased $158.6 million worth of Ethereum [1] Market Prediction - Expects Ethereum price to reach $10,000 [1]

1. 申报重点领域 北京市重点实验室的布局将紧密围绕北京国际科技创新中心建设，重点支持以下领域： 新一代信息技术（如人工智能、大数据、5G/6G通信等）； 智能制造与装备（如工业互联网、智能机器人、高端装备制造等）； 新材料（如高性能材料、纳米材料、新能源材料等）； 新能源（如清洁能源、储能技术、碳中和相关技术等）。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们 的推送。 7月9日， 北京市科学技术委员会、中关村科技园区管理委员会联合发布了《2025年北京市重 点实验室申报指南》（京科机发〔2025〕135号）， 正式启动本年度北京市重点实验室申报 工作 。2025年北京市重点实验室申报工作紧密围绕北京国际科技创新中心建设的重点任务， 聚焦本市重点产业方向和前沿科技领域。申报领域 涵盖新一代信息技术、 医药健康、智能制 造与装备、新材料、新能源、农业科技 、智慧城市等关键领域。 （ 文 末 附 申 报 案 例 ） 医药健康（如生物医药、医疗器械、精准医疗等）； 智能制造与装备作为核心方向之一，将重点关注工业自动化、智能检测、数字孪生、工业软件 等 ...

ETHEREUM IS PUMPING HARD 🚀 https://t.co/86IyBpwdtt ...

RT Token Terminal 📊 (@tokenterminal)🏦 Top RWA issuers (by AUM):BlackRock, Ondo, Superstate, WisdomTree, Franklin Templeton, Blockchain Capital, Apollo, VanEck, Hamilton Lane⛓️ Top RWA chains (by AUM):Ethereum, Solana, zkSync Era, Arbitrum One, Avalanche, Aptos, Polygon, Base, Plume Network, OP Mainnet https://t.co/J2n1QY1WFm ...

RT Token Terminal 📊 (@tokenterminal)🚨 ICYMI: Active loans on @ethereum have increased by ~$21 billion since January '23. https://t.co/AgWm1qvLIi ...

Core Insights - The Phase 3 Orbit study for UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is on track for final analysis by the end of the year [1][3] - The Data Monitoring Committee has confirmed an acceptable safety profile for UX143, allowing the study to proceed [2] - Ultragenyx and Mereo BioPharma are collaborating on the development of setrusumab, targeting OI sub-types I, III, and IV [5][12] Study Details - The Phase 3 Orbit study has enrolled 159 patients across 45 sites in 11 countries, with a primary efficacy endpoint focused on annualized clinical fracture rate [7] - The Cosmic study, which is also in Phase 3, has enrolled 69 patients aged 2 to <7 years, comparing setrusumab to intravenous bisphosphonates [8] - Both studies will conduct final analyses after patients have been on therapy for at least 18 months, with specific statistical thresholds set for each study [4] Background on Osteogenesis Imperfecta - OI is a genetic disorder affecting bone metabolism, primarily caused by mutations in the COL1A1 or COL1A2 genes, leading to increased bone brittleness and a high rate of fractures [9] - Approximately 60,000 individuals are affected by OI in commercially accessible regions, with no globally approved treatments available [9] Mechanism of Setrusumab - Setrusumab is a fully human monoclonal antibody that inhibits sclerostin, which negatively regulates bone formation, potentially increasing bone mass and strength [10] - Previous studies have shown that anti-sclerostin antibodies can significantly improve bone formation and density in OI models [11] Company Profiles - Ultragenyx is focused on developing therapies for rare genetic diseases, with a portfolio aimed at addressing high unmet medical needs [13] - Mereo BioPharma is also dedicated to innovative therapeutics for rare diseases, with setrusumab as one of its key candidates [15]

🏦 Top RWA issuers (by AUM):BlackRock, Ondo, Superstate, WisdomTree, Franklin Templeton, Blockchain Capital, Apollo, VanEck, Hamilton Lane⛓️ Top RWA chains (by AUM):Ethereum, Solana, zkSync Era, Arbitrum One, Avalanche, Aptos, Polygon, Base, Plume Network, OP Mainnet https://t.co/J2n1QY1WFm ...

"Because decentralization is the direction of travel for the world, we believe that we’re going to see Ether and Bitcoin continue to rise over the next years and decades as we paradigm shift to more and more decentralization."- @ethereumJosephSBET (SharpLink Gaming) (@SharpLinkGaming):Here to tell Ethereum's story https://t.co/Eai9te64Lj ...